Tagra Biotechnologies Overview
Tagra Biotechnologies is a manufacturer and developer of cosmetic ingredients, microencapsulation technology, and skin delivery systems. The company is focused on using its technology to overcome technical challenges, with the goal of creating successful beauty products. Tagras ingredients are globally compliant; free of preservatives, surfactants, and allergens; Halal certified; non-nano-sized and compliant with nano regulations; and not tested on animals and free of any animal-derived materials. The companys microencapsulations create visual and sensory effects, such as color and texture transitions, designed to engage and delight the end consumer. In addition, its stabilized actives are delivered fresh with release on demand (RND) for improved anti-aging benefits.
Latest News
N/A
Caldic UK Ltd signs agreement with Tagra Biotechnologies
The article does not provide any specific information about a company or event.
growth-positive
Tagra Biotechnologies: Improving cosmetic microencapsulation to create new user experiences
Tagra Biotechnologies has developed a unique microencapsulation process that overcomes formulation challenges in the cosmetics industry. The company has issued 14 patents for its microencapsulation technology, which combines high loading, optimal protection, a release on demand mechanism, and manufacturing tolerance. Tagras microcapsules can hold high volumes of ingredients, withstand manufacturing processes, and protect actives from degradation. The technology is versatile and can be used in a range of cosmetic formulations. Tagra offers products such as vegan microencapsulation pigments for visual effects and cellulose-based microcapsules for clinical results. The companys encapsulated materials also provide enhanced stability and improved compatibility. Tagras technology allows for seamless scale-up and can be incorporated into various cosmetic formulations. The article highlights the benefits and applications of Tagras microencapsulation technology.
CustomersPartners
growth-positive
Azelis strengthens ties with Tagra Biotechnologies and its position in Asia Pacific with an exclusive distribution agreement in China
Azelis has been appointed as the exclusive distributor by Tagra Biotechnologies to offer their range of RND® microencapsulated actives and pigments in China for all Personal Care applications. This partnership will reinforce Azeliss position in Asia Pacific as a leading distributor of specialty chemicals. The partnership is an extension of agreements between the two companies in Europe, Canada, Australia, and New Zealand. Azelis and Tagra aim to offer customers high-quality technical service and innovative application insights. The agreement is effective immediately.
Partners
growth-positive
Tagra's Innovative Technologies Provide Formulators a New Kind of Freedom Inside a Range of Encapsulated Sun Screens and UV Filters
Tagra Biotechnologies has developed a breakthrough in microencapsulation technology for UV filters. The companys new SunCap™ products offer a wide range of approved organic and inorganic UV filters. The patented microencapsulation technology allows for the stabilization and prevention of the release of UV filters into the surroundings. This technology provides benefits such as retaining sunscreen on the skin, improving safety and photoprotection against UV radiation, reducing systemic absorption, increasing photostability, and achieving high SPF values. The SunCap™ range currently includes AvoCap™, encapsulated avobenzone, and TitanCap™, encapsulated TiO2. Tagra Biotechnologies is actively seeking partnerships and customers for their innovative products.
PartnersCustomers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Mature |
| Rounds | 0 |
| Investors | 0 |
Team Members
1
Employees: 11-50
Locations
HaMelacha Street 8, Netanya, Israel
Photos & Videos
3 item(s)
Tagra Biotechnologies Business
Business models
B2C, B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyCosmetic MaterialsTarget Customer
Healthcare & Life SciencesLife SciencesCosmeticsConsumersDemographics & FamilyWomenCommerce & RetailConsumer GoodsBeauty & CosmeticsCore Technology
Materials & SubstancesTags (9)
dermatologydrug-deliverypharma-companiesbiotechnologycosmeticsskin-carebiopharmaceuticalsustained-releasecosmetic-companiesGeographic Markets
IsraelTagra Biotechnologies Financials
Undisclosed
Total funding
—
Capital raised
Undisclosed
Last funding
Mature
Funding stage
0
Total rounds
0
Investors
Tagra Biotechnologies Lifecycle
Tagra Biotechnologies News
4 articles
N/A
Caldic UK Ltd signs agreement with Tagra Biotechnologies
The article does not provide any specific information about a company or event.
growth-positive
Tagra Biotechnologies: Improving cosmetic microencapsulation to create new user experiences
Tagra Biotechnologies has developed a unique microencapsulation process that overcomes formulation challenges in the cosmetics industry. The company has issued 14 patents for its microencapsulation technology, which combines high loading, optimal protection, a release on demand mechanism, and manufacturing tolerance. Tagras microcapsules can hold high volumes of ingredients, withstand manufacturing processes, and protect actives from degradation. The technology is versatile and can be used in a range of cosmetic formulations. Tagra offers products such as vegan microencapsulation pigments for visual effects and cellulose-based microcapsules for clinical results. The companys encapsulated materials also provide enhanced stability and improved compatibility. Tagras technology allows for seamless scale-up and can be incorporated into various cosmetic formulations. The article highlights the benefits and applications of Tagras microencapsulation technology.
CustomersPartners
growth-positive
Azelis strengthens ties with Tagra Biotechnologies and its position in Asia Pacific with an exclusive distribution agreement in China
Azelis has been appointed as the exclusive distributor by Tagra Biotechnologies to offer their range of RND® microencapsulated actives and pigments in China for all Personal Care applications. This partnership will reinforce Azeliss position in Asia Pacific as a leading distributor of specialty chemicals. The partnership is an extension of agreements between the two companies in Europe, Canada, Australia, and New Zealand. Azelis and Tagra aim to offer customers high-quality technical service and innovative application insights. The agreement is effective immediately.
Partners
growth-positive
Tagra's Innovative Technologies Provide Formulators a New Kind of Freedom Inside a Range of Encapsulated Sun Screens and UV Filters
Tagra Biotechnologies has developed a breakthrough in microencapsulation technology for UV filters. The companys new SunCap™ products offer a wide range of approved organic and inorganic UV filters. The patented microencapsulation technology allows for the stabilization and prevention of the release of UV filters into the surroundings. This technology provides benefits such as retaining sunscreen on the skin, improving safety and photoprotection against UV radiation, reducing systemic absorption, increasing photostability, and achieving high SPF values. The SunCap™ range currently includes AvoCap™, encapsulated avobenzone, and TitanCap™, encapsulated TiO2. Tagra Biotechnologies is actively seeking partnerships and customers for their innovative products.
PartnersCustomers
Tagra Biotechnologies Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 25 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
Tagra Biotechnologies Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 91/100 |
| Missing | funding rounds, markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 512645649 |
| Crunchbase | tagra-biotechnologies-ltd |
| Phone | +97298656454 |
| Last updater | Orli Wollner |
| Updater email | orlushka@gmail.com |
| Last update | 2020-08-16T00:00:00.000Z |
| Created | 2014-11-24T00:00:00.000Z |